Concise Prescribing Info
Disorders associated w/ reduced GI motility.
Dosage/Direction for Use
Adult : PO 50 mg tid, may reduce depending on the patient's age and symptoms.
Dosage Details
Disorders associated with reduced gastrointestinal motility
Adult: 50 mg tid. May reduce dose depending on the patient’s age and symptoms.
GI haemorrhage, mechanical obstruction or perforation, Parkinson’s disease.
Special Precautions
Hepatic and renal impairment. Pregnancy and lactation.
Adverse Reactions
Diarrhoea, abdominal pain, constipation, headache, dizziness, nausea, increased salivation, leucopenia, thrombocytopenia, tremor, rash, redness and itching, anaphylactoid reactions, gynaecomastia, increased prolactin, AST and ALT, jaundice.
Drug Interactions
May reduce the effect w/ anticholinergic drugs.
Description: Itopride increases acetylcholine concentrations by inhibiting dopamine D2 receptors and acetylcholinesterase, resulting in enhancement of GI motility.
Absorption: Rapidly and almost completely absorbed from the GI tract. Bioavailability: 60%. Time to peak plasma concentration: 0.5-0.75 hr.
Distribution: Plasma protein binding: Approx 96%, mainly to albumin.
Metabolism: Undergoes extensive hepatic metabolism.
Excretion: Via urine. Terminal half-life: Approx 6 hr.
Chemical Structure

Click on icon to see table/diagram/image
Store between 15-30°C.
ATC Classification
A03FA07 - itopride ; Belongs to the class of propulsives. Used in the treatment of functional gastrointestinal disorders.
Disclaimer: This information is independently developed by MIMS based on Itopride from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in